T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1776
ACM Research
ACMR
$5.52B
| $1.87M | ﹤0.01% |
47,349
+1,981
| +4% | +$73.8K |
|
1777
Andersons Inc
ANDE
$2.24B
| $1.86M | ﹤0.01% |
35,007
+1,471
| +4% | +$72K |
|
1778
Trinity Industries
TRN
$2.36B
| $1.86M | ﹤0.01% |
70,395
+1,810
| +3% | +$49.2K |
|
1779
Peoples Bancorp
PEBO
$1.48B
| $1.86M | ﹤0.01% |
61,958
+5,749
| +10% | +$171K |
|
1780
Lakeland Financial Corp
LKFN
$1.56B
| $1.86M | ﹤0.01% |
32,585
+6,257
| +24% | +$372K |
|
1781
RingCentral
RNG
$5.38B
| $1.86M | ﹤0.01% |
64,296
-2,215
| -3% | -$63.1K |
|
1782
Pediatrix Medical
MD
$2.16B
| $1.85M | ﹤0.01% |
86,572
+3,790
| +5% | +$77.7K |
|
1783
Nicolet Bankshares
NIC
$3.75B
| $1.85M | ﹤0.01% |
15,265
+496
| +3% | +$62.7K |
|
1784
Seadrill
SDRL
$2.99B
| $1.85M | ﹤0.01% |
53,478
-384,682
| -88% | -$12M |
|
1785
German American Bancorp
GABC
$1.93B
| $1.83M | ﹤0.01% |
46,675
+4,027
| +9% | +$159K |
|
1786
Amneal Pharmaceuticals
AMRX
$6.16B
| $1.82M | ﹤0.01% |
144,704
+7,015
| +5% | +$80.3K |
|
1787
Northwest Bancshares
NWBI
$2.32B
| $1.82M | ﹤0.01% |
151,949
+10,647
| +8% | +$130K |
|
1788
Cohen & Steers
CNS
$4.37B
| $1.82M | ﹤0.01% |
28,934
+4,863
| +20% | +$316K |
|
1789
LiveRamp
RAMP
$2.3B
| $1.82M | ﹤0.01% |
61,819
+21,221
| +52% | +$609K |
|
|
GTY
1790
Getty Realty Corp
GTY
$2.07B
| $1.81M | ﹤0.01% |
66,260
+3,315
| +5% | +$91.6K |
|
1791
Crane NXT
CXT
$2.97B
| $1.81M | ﹤0.01% |
38,411
+1,767
| +5% | +$104K |
|
1792
Kaiser Aluminum
KALU
$2.98B
| $1.8M | ﹤0.01% |
15,712
+1,346
| +9% | +$128K |
|
1793
Invesco QQQ Trust
QQQ
$485B
| $1.8M | ﹤0.01% |
2,937
-825,447
| -100% | -$507M |
|
1794
Vericel Corp
VCEL
$2.27B
| $1.79M | ﹤0.01% |
49,834
+5,745
| +13% | +$211K |
|
1795
IPG Photonics
IPGP
$3.67B
| $1.79M | ﹤0.01% |
25,007
+795
| +3% | +$64.9K |
|
1796
QuidelOrtho
QDEL
$1B
| $1.78M | ﹤0.01% |
62,439
+2,781
| +5% | +$75.3K |
|
1797
Adient
ADNT
$1.59B
| $1.78M | ﹤0.01% |
92,947
+1,065
| +1% | +$22.4K |
|
1798
Knowles
KN
$3.29B
| $1.78M | ﹤0.01% |
83,123
-20,597
| -20% | -$469K |
|
1799
Comstock Resources
CRK
$4.13B
| $1.78M | ﹤0.01% |
76,641
+2,220
| +3% | +$48.9K |
|
1800
Diamondrock Hospitality Co
DRH
$2.53B
| $1.77M | ﹤0.01% |
197,532
+8,420
| +4% | +$71.7K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.